Rituximab in Systemic Sclerosis

Summary

Rituximab in Systemic Sclerosis is a clinical trial^[1].

Key Facts

• Rituximab in Systemic Sclerosis is in the country of France^[2].
• Rituximab in Systemic Sclerosis's instance of is recorded as clinical trial^[3].
• Rituximab in Systemic Sclerosis's start time is recorded as +2013-04-09T00:00:00Z^[4].
• Rituximab in Systemic Sclerosis's end time is recorded as +2016-04-18T00:00:00Z^[5].
• Rituximab in Systemic Sclerosis's main subject is recorded as arthritis^[6].
• Rituximab in Systemic Sclerosis's main subject is recorded as sclerosis^[7].
• Rituximab in Systemic Sclerosis's number of participants is recorded as {'unit': '1', 'amount': '+22'}^[8].
• Rituximab in Systemic Sclerosis's title is recorded as Evaluation of Rituximab in Systemic Sclerosis Associated Polyarthritis^[9].
• Rituximab in Systemic Sclerosis's short name is recorded as RECOVER^[10].
• Rituximab in Systemic Sclerosis's minimum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+18'}^[11].
• Rituximab in Systemic Sclerosis's ClinicalTrials.gov ID is recorded as NCT01748084^[12].
• Rituximab in Systemic Sclerosis's maximum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+80'}^[13].
• Rituximab in Systemic Sclerosis's research intervention is recorded as rituximab^[14].
• Rituximab in Systemic Sclerosis's research intervention is recorded as methylprednisolone hemisuccinate^[15].
• Rituximab in Systemic Sclerosis's research intervention is recorded as prednisolone^[16].
• Rituximab in Systemic Sclerosis's research intervention is recorded as methylprednisolone^[17].
• Rituximab in Systemic Sclerosis's research intervention is recorded as prednisolone acetate^[18].
• Rituximab in Systemic Sclerosis's research intervention is recorded as prednisolone 21-phosphate^[19].
• Rituximab in Systemic Sclerosis's clinical trial phase is recorded as phase II clinical trial^[20].
• Rituximab in Systemic Sclerosis's clinical trial phase is recorded as phase III clinical trial^[21].
• Rituximab in Systemic Sclerosis's research site is recorded as Cochin hospital chapel^[22].
• Rituximab in Systemic Sclerosis's study type is recorded as interventional study^[23].